tmem237a Antibody

What is TMEM237 and why is it important in research?

TMEM237 is a transmembrane protein belonging to the transmembrane protein (TMEM) family. It plays significant roles in membrane trafficking between the inner and outer segments of retinal photoreceptors and has been implicated in Joubert syndrome when mutated . Recent research has revealed that TMEM237 is upregulated under hypoxic conditions in hepatocellular carcinoma (HCC) and contributes to cancer progression by interacting with NPHP1 to activate the Pyk2/ERK pathway . The protein is also a component of the photoreceptor outer segment plasma membrane . Due to its involvement in disease pathways and cellular processes, TMEM237 has become an important target for researchers studying retinal biology, Joubert syndrome, and liver cancer.

What is the molecular weight of TMEM237 and how does this affect antibody selection?

The calculated molecular weight of TMEM237 is approximately 45.5 kDa, but the observed molecular weight in Western blot analyses is typically around 72 kDa . This discrepancy between calculated and observed molecular weights is likely due to post-translational modifications such as glycosylation, phosphorylation, or other modifications that affect protein migration during gel electrophoresis. When selecting antibodies for TMEM237 detection, researchers should consider antibodies validated to detect the 72 kDa form in their experimental system. Always verify the expected band size in your specific tissue or cell type, as expression patterns and post-translational modifications can vary between systems.

Which species reactivity should be considered when selecting a TMEM237 antibody?

Commercial TMEM237 antibodies are typically validated for reactivity with human and mouse TMEM237 . When planning experiments, researchers should verify the species cross-reactivity of the selected antibody. The sequence homology between species should be considered, especially when working with less common model organisms. For example, the anti-ALS2CR4 TMEM237 antibody (catalog #A30569) has been validated for both human and mouse samples . If working with other species, a sequence alignment analysis should be performed to predict potential cross-reactivity, followed by experimental validation.

What are the optimal techniques for detecting TMEM237 expression in tissue samples?

Multiple techniques can be employed to detect TMEM237 expression, with selection depending on research requirements:

• RT-qPCR: For mRNA expression analysis, using validated primers (Forward: 5′-AGAGCACCATGAGGACTGAC, Reverse: 5′-AGTTGATGGCTCATTGCCCT) . This technique is highly sensitive for quantifying transcript levels but doesn't provide information about protein localization or post-translational modifications.

• Western Blotting: Recommended antibody dilutions range from 1:500 to 1:2000 . Expected band size is approximately 72 kDa. This technique provides semi-quantitative information about protein expression levels.

• Immunohistochemistry (IHC): Useful for visualizing spatial distribution within tissues. After dewaxing and antigen retrieval, primary antibody incubation should be performed at 4°C overnight, followed by secondary antibody incubation at room temperature .

• Quantitative Mass Spectrometry: For precise quantification, MS with cold isotope-labeled peptide standards can determine absolute amounts of TMEM237 .

Each method offers distinct advantages, and combining multiple approaches provides more comprehensive insights into TMEM237 expression patterns.

How can researchers effectively validate TMEM237 antibody specificity?

Validating antibody specificity is crucial for reliable research outcomes. A comprehensive validation approach should include:

• Positive and negative controls: Use tissues/cells known to express high levels of TMEM237 (such as HCC cell lines) as positive controls and tissues with minimal expression as negative controls .

• Knockdown/knockout validation: Perform Western blot or immunostaining after TMEM237 knockdown using siRNA or shRNA to confirm signal reduction .

• Recombinant protein: Use overexpressed tagged versions of TMEM237 to confirm antibody detection at the expected molecular weight .

• Peptide competition assay: Pre-incubation of the antibody with its immunizing peptide should abolish or significantly reduce the specific signal.

• Cross-validation: Compare results using multiple antibodies targeting different epitopes of TMEM237, if available.

These validation steps ensure that the observed signals truly represent TMEM237 rather than non-specific binding or cross-reactivity.

What is the optimal sample preparation protocol for TMEM237 immunostaining in tissue sections?

For optimal TMEM237 immunostaining in tissue sections, the following protocol is recommended:

• Fixation: Use 4% paraformaldehyde fixation for preservation of antigen structure and tissue morphology.

• Sectioning: For paraffin-embedded tissues, prepare 5-10 μm sections.

• Dewaxing and rehydration: Process sections through xylene and graded alcohol series.

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) is essential as formaldehyde fixation can mask epitopes .

• Blocking: Block with 5-10% normal serum (matching the species of the secondary antibody) with 0.1-0.3% Triton X-100 for 1-2 hours at room temperature.

• Primary antibody incubation: Dilute antibody appropriately (experimentally determined) and incubate at 4°C overnight .

• Secondary antibody: Incubate with appropriate HRP-conjugated or fluorescently-labeled secondary antibody at room temperature for 1-2 hours.

• Counterstaining: For brightfield microscopy, counterstain with hematoxylin; for fluorescence, use DAPI for nuclear visualization .

This protocol may require optimization based on tissue type and fixation conditions.

How should researchers quantify TMEM237 expression levels in immunohistochemistry studies?

For rigorous quantification of TMEM237 expression in IHC studies, a standardized scoring system should be implemented:

• Staining intensity score: Evaluate on a scale of:

  • 0 (negative)

  • 1 (weak)

  • 2 (medium)

  • 3 (strong)

• Percentage score: Define as:

  • 0 (negative)

  • 1 (1–25%)

  • 2 (26–50%)

  • 3 (51–75%)

  • 4 (76–100%)

• Final IHC score calculation: Multiply the staining intensity score by the percentage score to obtain a comprehensive evaluation (range: 0-12) .

• Blinded assessment: Have at least two independent observers score the samples blindly to reduce subjective bias.

• Validation: Compare IHC results with other quantitative methods such as Western blotting or RT-qPCR when possible.

This systematic approach enables statistical analysis of TMEM237 expression across different experimental groups or clinical samples.

What are the expected TMEM237 molar ratios in photoreceptor cells and how can this be accurately measured?

In photoreceptor cells, TMEM237 is expressed at relatively low levels compared to rhodopsin. Specific quantitative measurements have shown:

To accurately measure these ratios, mass spectrometry with cold isotope-labeled peptide standards is the preferred method . This approach requires:

• Purification of rod outer segments (ROS) from retinal tissue

• Digestion of proteins with trypsin

• Addition of known quantities of isotope-labeled TMEM237 peptides as internal standards

• LC-MS/MS analysis to compare labeled vs. unlabeled peptide intensities

• Calculation of absolute amounts using standard curves

This quantitative data is essential for modeling the stoichiometry of TMEM237 in protein complexes and understanding its function in normal and disease states.

How can researchers accurately assess subcellular localization of TMEM237 in photoreceptors?

To precisely determine the subcellular localization of TMEM237 in photoreceptors, researchers should employ multiple complementary approaches:

• Immunofluorescence with confocal microscopy: Use co-localization with established marker proteins for different photoreceptor compartments (e.g., rhodopsin for outer segments, NCKX1 for plasma membrane).

• Serial tangential sectioning with quantitative proteomics: Cut serial 10-μm-thick tangential sections through the photoreceptor layer of a flat-mounted retina and determine relative amounts of TMEM237 in each section using label-free quantitative proteomics . Compare distribution with known markers like ABCA4 (evenly distributed throughout OS length).

• Immuno-electron microscopy: For nanometer-scale resolution of TMEM237 localization, use gold-labeled secondary antibodies to visualize the protein in ultrathin sections.

• Subcellular fractionation: Biochemically separate different photoreceptor compartments and analyze TMEM237 distribution by Western blotting.

Research has shown that TMEM237 is relatively evenly distributed throughout the outer segment length, similar to ABCA4, rather than being concentrated at the outer segment base as previously suggested .

What are the optimal experimental designs for studying TMEM237 protein interactions?

To investigate TMEM237 protein interactions, several complementary approaches should be considered:

• Co-immunoprecipitation (Co-IP):

  • Lyse cells in a buffer containing 1% NP-40 or Triton X-100, 150 mM NaCl, 50 mM Tris (pH 7.4), and protease inhibitors

  • Immunoprecipitate with anti-TMEM237 antibody and protein A/G beads

  • Analyze precipitated complexes by Western blotting for potential interacting partners

  • For validation, perform reciprocal Co-IP using antibodies against suspected interacting proteins

• Proximity Ligation Assay (PLA):

  • For detecting protein interactions in situ with high sensitivity

  • Requires antibodies against TMEM237 and potential interactors from different species

  • Provides spatial information about where interactions occur within cells

• Mass Spectrometry-Based Interactome Analysis:

  • Immunoprecipitate TMEM237 from cell lysates

  • Analyze precipitated proteins by mass spectrometry

  • Previous studies identified NPHP1 as an interacting partner using this approach

• Recombinant Protein Expression and Pull-down:

  • Express tagged versions (FLAG-tagged TMEM237 and HA-tagged partner proteins)

  • Perform Co-IP with anti-FLAG or anti-HA antibodies

  • This approach validated the interaction between TMEM237 and NPHP1

Combining these methods provides robust evidence for protein-protein interactions and helps eliminate false positives.

How can researchers investigate the role of TMEM237 in hypoxia-induced pathways?

To investigate TMEM237's role in hypoxia-induced pathways, a comprehensive experimental approach should include:

• Hypoxia Induction Models:

  • In vitro: Culture cells in hypoxic chambers (1% O₂) or treat with chemical hypoxia mimetics (CoCl₂, DFO)

  • In vivo: Use partial hepatectomy models or hypoxic chambers for animal studies

• Transcriptional Regulation Analysis:

  • Chromatin immunoprecipitation (ChIP) assays to determine if HIF-1α directly binds to the TMEM237 promoter

  • Use primers targeting the TMEM237 HRE (hypoxia-responsive element): Forward 5′-GAACCTTTCGCAGATTTCACA, Reverse 5′-TTTCCTTGTAGGCCGATTTG

  • Luciferase reporter assays with wild-type and mutated TMEM237 promoter constructs to verify functional significance of HRE sites

• Signaling Pathway Analysis:

  • Western blotting for phosphorylated and total forms of Pyk2 and ERK to assess pathway activation

  • Use specific inhibitors of HIF-1α (e.g., 2-methoxyestradiol), Pyk2 (e.g., PF-4618433), and ERK (e.g., U0126) to confirm pathway dependencies

• Functional Assays Under Hypoxia:

  • Compare proliferation, migration, and invasion of cells with TMEM237 knockdown vs. controls under hypoxic conditions

  • Measure markers of EMT (E-cadherin, N-cadherin, vimentin) to assess phenotypic changes

This integrated approach would provide mechanistic insights into how TMEM237 contributes to hypoxia-induced cellular responses.

What are the critical considerations for designing TMEM237 knockout/knockdown experiments in cancer models?

When designing TMEM237 knockout/knockdown experiments in cancer models, researchers should consider these critical factors:

• Selection of Appropriate Models:

  • Cell lines: Choose multiple cell lines with varying baseline TMEM237 expression levels (e.g., Huh7, PLC/PRF/5, HepG2, MHCC97L, MHCC97H, and HCCLM3 for HCC studies)

  • Animal models: Consider both subcutaneous xenograft models for tumor growth and tail vein injection models for metastasis assessment

• Knockdown/Knockout Strategy Selection:

  • Transient siRNA: For short-term experiments (3-5 days)

  • Stable shRNA: For longer experiments and in vivo studies

  • CRISPR-Cas9: For complete gene knockout, targeting early exons

  • Inducible systems: Consider doxycycline-inducible shRNA or Cas9 for temporal control of TMEM237 depletion

• Validation Requirements:

  • Confirm knockdown/knockout efficiency at both mRNA (RT-qPCR) and protein (Western blot) levels

  • Use multiple independent siRNA/shRNA sequences or sgRNAs to rule out off-target effects

  • Include appropriate controls (non-targeting siRNA/shRNA or non-targeting sgRNA)

• Comprehensive Phenotypic Analysis:

  • In vitro: Assess proliferation, colony formation, migration, invasion, and EMT marker expression

  • In vivo: Monitor tumor growth, weight, and metastatic potential

  • Molecular analysis: Examine downstream pathways (e.g., Pyk2/ERK signaling) to confirm mechanism

• Rescue Experiments:

  • Re-express TMEM237 that is resistant to the knockdown strategy to confirm specificity

  • Express mutant forms of TMEM237 (e.g., mutated in the NPHP1 interaction domain) to dissect functional domains

These considerations ensure robust and reproducible results when investigating TMEM237's role in cancer progression.

How can researchers address non-specific binding issues with TMEM237 antibodies?

Non-specific binding can significantly impact experimental results. To address these issues with TMEM237 antibodies:

• Optimization of Blocking Conditions:

  • Test different blocking agents (BSA, non-fat dry milk, normal serum, commercial blocking buffers)

  • Increase blocking time (2-3 hours at room temperature or overnight at 4°C)

  • Consider adding 0.1-0.3% Triton X-100 or Tween-20 to reduce hydrophobic interactions

• Antibody Dilution Optimization:

  • Perform titration experiments with serial dilutions (e.g., 1:500, 1:1000, 1:2000, 1:5000)

  • Optimal dilution provides specific signal with minimal background

  • For Western blotting, recommended dilutions are 1:500-1:2000

• Inclusion of Appropriate Controls:

  • Peptide competition assay to confirm specificity

  • TMEM237 knockout/knockdown samples as negative controls

  • Omission of primary antibody to assess secondary antibody background

• Buffer Optimization:

  • Increase salt concentration (up to 500 mM NaCl) to reduce ionic interactions

  • Add detergents (0.1-0.5% Triton X-100) to reduce hydrophobic interactions

  • Consider adding specific blockers for endogenous biotin or immunoglobulins if present in your samples

• Antibody Purification:

  • For polyclonal antibodies, consider affinity purification against the immunizing peptide

  • Pre-absorb antibody against tissues/cells lacking TMEM237 expression

Implementing these strategies systematically can significantly improve signal-to-noise ratio in TMEM237 detection assays.

What are the optimal protocols for quantifying TMEM237 expression in heterogeneous tissue samples?

Quantifying TMEM237 in heterogeneous tissues requires specialized approaches to account for cellular diversity:

• Laser Capture Microdissection (LCM):

  • Isolate specific cell populations from heterogeneous tissues

  • Process captured cells for RNA extraction and RT-qPCR or protein extraction and Western blotting

  • Provides cell type-specific expression data

• Single-Cell RNA Sequencing:

  • Dissociate tissues into single cells and perform scRNA-seq

  • Analyze TMEM237 expression across different cell clusters

  • Provides comprehensive cell type-specific expression profiles

• Multiplex Immunofluorescence:

  • Co-stain for TMEM237 and cell type-specific markers

  • Use spectral imaging to separate fluorophores

  • Quantify TMEM237 signal intensity specifically in positively-marked cell populations

• Digital Spatial Profiling:

  • Combines immunofluorescence with spatial transcriptomics

  • Allows quantification of TMEM237 in specific regions of tissue sections

  • Preserves spatial context while providing quantitative data

• Image Analysis for IHC Quantification:

  • Use color deconvolution algorithms to separate DAB and hematoxylin staining

  • Apply machine learning-based cell segmentation

  • Calculate H-scores (combining intensity and percentage) with formula:
    H-score = 1 × (% of cells with weak staining) + 2 × (% with moderate staining) + 3 × (% with strong staining)

These approaches provide more accurate quantification of TMEM237 expression in complex tissues than traditional bulk analysis methods.

How should researchers address data discrepancies between different TMEM237 detection methods?

When faced with discrepancies between different TMEM237 detection methods, researchers should implement a systematic troubleshooting approach:

• Identify Potential Sources of Discrepancy:

  Detection Method	Potential Limitations
  RT-qPCR	Measures mRNA, not protein; primer efficiency variations; reference gene stability
  Western Blot	Post-translational modifications; extraction efficiency; antibody specificity
  IHC/IF	Epitope masking; fixation artifacts; antibody specificity; subjective scoring
  Mass Spectrometry	Sample preparation bias; ionization efficiency; peptide selection

• Methodological Validation Steps:

  • For RT-qPCR: Verify primer specificity, efficiency, and reference gene stability

  • For Western blot: Test multiple antibodies targeting different epitopes

  • For IHC: Compare different fixation and antigen retrieval methods

  • For all antibody-based methods: Include peptide competition controls

• Biological Explanations for Discrepancies:

  • Post-transcriptional regulation may cause mRNA-protein discrepancies

  • Post-translational modifications may affect antibody recognition

  • Subcellular localization differences may impact extraction efficiency

  • Protein stability and turnover rates may vary between conditions

• Resolution Framework:

  • Prioritize methods that directly measure the parameter of interest

  • For protein quantification, mass spectrometry with isotope-labeled standards provides absolute quantification

  • Consider orthogonal validation with genetic approaches (e.g., tagged knock-in constructs)

  • Report discrepancies transparently in publications, discussing potential biological significance

Understanding that different methods measure different aspects of gene expression (transcript vs. protein vs. localization) can often explain apparent discrepancies and provide complementary rather than contradictory information.

What emerging technologies show promise for advancing TMEM237 research?

Several cutting-edge technologies hold significant potential for advancing TMEM237 research:

• Proximity Labeling Techniques:

  • BioID or TurboID fusion with TMEM237 to identify proximal proteins in living cells

  • APEX2 fusion for electron microscopy-compatible proximity labeling

  • These approaches can reveal the TMEM237 interactome in its native cellular context

• Super-Resolution Microscopy:

  • STORM, PALM, or STED microscopy to visualize TMEM237 distribution with nanometer precision

  • Can resolve TMEM237 localization within membrane microdomains beyond the diffraction limit

  • Particularly valuable for studying TMEM237 in photoreceptor outer segments

• Cryo-Electron Microscopy:

  • Structural determination of TMEM237 alone or in complex with interacting partners

  • May reveal how mutations associated with Joubert syndrome affect protein structure

• CRISPR-Based Techniques:

  • CRISPRi/CRISPRa for fine-tuned modulation of TMEM237 expression

  • Base editing or prime editing for introducing specific disease-associated mutations

  • CRISPR knock-in of fluorescent tags at endogenous loci for live-cell imaging

• Organoid Models:

  • Retinal organoids for studying TMEM237 in photoreceptor development

  • Liver organoids for investigating TMEM237 in HCC in a 3D context

  • Patient-derived organoids to study disease-specific mutations

These technologies promise to provide deeper insights into TMEM237 function, localization, interactions, and disease mechanisms.

How can researchers integrate multi-omics approaches to better understand TMEM237 regulation and function?

A comprehensive multi-omics strategy for TMEM237 research should integrate:

• Genomics and Epigenomics:

  • Whole genome/exome sequencing to identify TMEM237 variants in patient cohorts

  • ChIP-seq for identifying transcription factors (e.g., HIF-1α) binding to the TMEM237 promoter

  • ATAC-seq to map chromatin accessibility at the TMEM237 locus

  • DNA methylation analysis to assess epigenetic regulation

• Transcriptomics:

  • RNA-seq following TMEM237 manipulation to identify downstream gene expression changes

  • Alternative splicing analysis to identify tissue-specific TMEM237 isoforms

  • Single-cell RNA-seq to map cell type-specific expression patterns

• Proteomics:

  • Quantitative proteomics to measure TMEM237 levels across conditions

  • Phosphoproteomics to identify downstream signaling effects of TMEM237 perturbation

  • Interaction proteomics (IP-MS) to map the TMEM237 interactome

• Metabolomics:

  • Metabolite profiling following TMEM237 manipulation to identify metabolic impacts

  • Particularly relevant in cancer contexts where metabolic reprogramming is common

• Data Integration Approaches:

  • Network analysis to identify functional modules connected to TMEM237

  • Machine learning algorithms to predict functional relationships

  • Causal inference methods to distinguish direct vs. indirect effects

Implementation example: Researchers could combine ChIP-seq to identify HIF-1α binding to the TMEM237 promoter, RNA-seq to confirm transcriptional upregulation under hypoxia, proteomics to identify interaction partners, and metabolomics to assess downstream metabolic effects in HCC cells. This integrated approach would provide a systems-level understanding of TMEM237's role in hypoxia response.

What are the most significant unresolved questions about TMEM237 that future research should address?

Several critical questions about TMEM237 remain unresolved and warrant focused investigation:

• Structural Biology:

  • What is the three-dimensional structure of TMEM237?

  • How do disease-associated mutations affect this structure?

  • What are the critical domains mediating protein-protein interactions?

• Physiological Function:

  • What is the precise molecular function of TMEM237 in photoreceptors?

  • How does TMEM237 contribute to membrane trafficking between inner and outer segments?

  • What is the evolutionary conservation of TMEM237 function across species?

• Disease Mechanisms:

  • How do TMEM237 mutations cause Joubert syndrome at the molecular level?

  • What is the mechanism by which TMEM237 promotes HCC progression beyond the Pyk2/ERK pathway?

  • Does TMEM237 play roles in other cancers or ciliopathies?

• Therapeutic Potential:

  • Can TMEM237 serve as a diagnostic or prognostic biomarker for HCC?

  • Is TMEM237 a viable therapeutic target for HCC treatment?

  • Could modulating TMEM237-NPHP1 interaction inhibit cancer progression?

• Regulatory Mechanisms:

  • Beyond HIF-1α, what other transcription factors regulate TMEM237 expression?

  • What post-translational modifications regulate TMEM237 function and stability?

  • How is TMEM237 trafficking and membrane localization regulated?

Addressing these questions will require interdisciplinary approaches combining structural biology, cell biology, genetics, and systems biology. The findings could have significant implications for understanding both fundamental cellular processes and disease mechanisms.